Login to Your Account

TransTech Signs $1B Diabetes Drug Deal with Forest Labs

By Donna Young

Wednesday, June 9, 2010
Privately held biotech TransTech Pharma Inc. stands to gain more than $1.1 billion in a new partnership with Forest Laboratories Inc. to develop and commercialize a new class of glucose-lowering agents, known as functionally liver-selective glucokinase activators (GKAs), to treat diabetes. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription